Stock analysts at Zacks Research decreased their FY2024 EPS estimates for AbbVie in a research report issued to clients and investors on Wednesday, January 15th. Zacks Research analyst S. Ganoria now ...
The global biologics contract development and manufacturing organization (cdmo) market size is estimated to grow by USD 16.32 ...
In the final days of the Biden administration, the U.S. Department of Health and Human Services’ Centers for Medicare and ...
AbbVie Inc. closed 17.25% short of its 52-week high of $207.32, which the company achieved on October 31st.
Zacks.com on MSN17h
Pharma Stock Roundup: J&J's ITCI Buyout, LLY's Weak Q4 SalesKey Takeaways JNJ will buy Intra-Cellular Therapies, producer of a drug for bipolar disorder, for $14.6 billion. Eli Lilly ...
AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $173.7 which represents a slight increase of $2.35 or 1.37% from the prior close of $171.35. The stock opened at $171.45 and touched a ...
Other AbbVie drugs, including its once-best-selling multiuse medication Humira, have been targeted by new provisions in the ...
Fierce Pharma Asia—AbbVie's $1B pact with Simcere; Takeda's launch map; Samsung Bio's growth plans
As the J.P. Morgan Healthcare Conference started in San Francisco on Monday, AbbVie linked up with Simcere with a $1 billion ...
Guggenheim Securities adjusted its financial outlook for shares of AbbVie Inc . (NYSE:ABBV), reducing the price target to $212 from the previous $221, while still recommending a Buy rating for the ...
The Department of Health and Human Services, through the Centers for Medicare & Medicaid Services, announced the selection of 15 additional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback